In research, induced pluripotent stem (iPS) cells are derived from skin, urine, or blood samples and developed into other cells, like heart tissue, that researchers want to study. Because of the similarities between certain dog and human diseases, canine iPS cells have potential uses in regenerative medicine and drug discovery.
Research on iPS cells is challenging because the cells are extremely sensitive to culture conditions. Before they are developed into other cells, iPS cells are in an undifferentiated state. At this stage, the cells are grown in a culture medium that provides the essential nutrients, growth factors, and signaling molecules that they require. However, optimizing these components is tricky, leading many cells to fail to maintain their pluripotency (ability to become any cell type) or differentiate in undesirable ways. As a result, the medium often constrains what researchers can achieve.
An international team led by Professor Shingo Hatoya of the Graduate School of Veterinary Science at Osaka Metropolitan University has developed a new culture medium, 'AR medium,' that transforms canine iPS cells into cardiomyocyte cells-the muscle cells that contract the heart.
Using AR medium, the researchers created the specific conditions required for proliferation in their undifferentiated state. They then established culture conditions suitable for the undifferentiated iPS cells to undergo differentiation into cardiac tissue. The result was cells that expressed genes and proteins that are only found in heart muscle cells.
The researchers also observed rhythmic contractions similar to a beating heart; the gold standard of whether the cells are functionally heart cells.
Far from simply being similar to heart muscle cells, these cells were functionally identical to cardiomyocytes. This would allow them to be used to test how new compounds affect heart rhythm, contractility, and safety before clinical trials and evaluate drug efficacy and safety.
Our research contributes to the development of treatments and could play an important role in preclinical studies for genetic abnormalities common to both humans and dogs that involve similar genetic pathways, such as dilated cardiomyopathy. Research using canine stem cells is expected to accelerate the development of regenerative medicine and genetic disease treatments for humans."
Professor Shingo Hatoya, Graduate School of Veterinary Science, Osaka Metropolitan University
The AR medium also potentially allows researchers to differentiate the iPS cells into cell types other than cardiomyocytes. Professor Hatoya is excited about the possibilities: "Using the medium would expand the potential use of iPS cells in regenerative medicine and allow researchers to investigate molecules to treat difficult-to-treat diseases including everything from heart and liver disease to neurological disorders."
The study was published in Stem Cell Reports.
Source:
Journal reference: